
A targeted treatment has had unprecedented success in shrinking a rare brain tumor, according to clinical trial results. These tumors are papillary craniopharyngiomas (PCPs), and the drug combo is called vemurafenib/cobimetinib. Each of 15 patients who received one or more cycles of targeted therapy responded to treatment, with an average 91% reduction in tumor size,… read on > read on >